Novartis AG (NYSE: NVS), a Swiss pharmaceutical giant listed on the NYSE under the ticker NVS, has commenced construction on two cutting-edge radioligand therapy (RLT) manufacturing facilities in the United States. The first initiative involves an expansion of the company’s current operations in Indianapolis, which will facilitate in-house production of isotopes essential for the creation of RLTs used in cancer treatments. Concurrently, Novartis is breaking ground on a state-of-the-art facility in California, marking its third RLT center in the country.
RLTs represent a frontier in precision medicine, merging a tumor-specific molecule, known as a ligand, with a radioactive isotope to direct radiation precisely to cancer cells while minimizing impact on neighboring healthy cells.
Anticipating a surge in demand for RLTs, Novartis is strategically bolstering its in-house supply chain capabilities. The company is at the forefront of innovation, investigating novel isotopes, ligands, and combination therapies with the ambition of extending RLT applications to a broader spectrum of cancer types, moving beyond the current focus on prostate and neuroendocrine tumors, as indicated in their recent press release. – Flcube.com
